M&R Capital Management Inc. Has $715,000 Stock Position in Bristol-Myers Squibb (NYSE:BMY)

M&R Capital Management Inc. reduced its position in Bristol-Myers Squibb (NYSE:BMY) by 14.2% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 11,181 shares of the biopharmaceutical company’s stock after selling 1,845 shares during the period. M&R Capital Management Inc.’s holdings in Bristol-Myers Squibb were worth $715,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. True Wealth Design LLC acquired a new stake in Bristol-Myers Squibb in the 4th quarter valued at about $26,000. GoalVest Advisory LLC acquired a new stake in Bristol-Myers Squibb during the first quarter worth approximately $29,000. Coppell Advisory Solutions Corp. acquired a new stake in Bristol-Myers Squibb during the fourth quarter worth approximately $31,000. Live Oak Investment Partners acquired a new stake in Bristol-Myers Squibb during the fourth quarter worth approximately $33,000. Finally, First Personal Financial Services lifted its position in Bristol-Myers Squibb by 67.8% during the first quarter. First Personal Financial Services now owns 495 shares of the biopharmaceutical company’s stock worth $34,000 after acquiring an additional 200 shares during the last quarter. 74.98% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Bristol-Myers Squibb

In related news, EVP Ann Powell sold 17,986 shares of the business’s stock in a transaction on Thursday, August 24th. The shares were sold at an average price of $61.25, for a total value of $1,101,642.50. Following the transaction, the executive vice president now owns 27,868 shares in the company, valued at $1,706,915. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other news, EVP Robert M. Plenge sold 732 shares of the company’s stock in a transaction dated Thursday, August 3rd. The shares were sold at an average price of $61.14, for a total transaction of $44,754.48. Following the transaction, the executive vice president now owns 6,584 shares in the company, valued at $402,545.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Ann Powell sold 17,986 shares of the company’s stock in a transaction dated Thursday, August 24th. The shares were sold at an average price of $61.25, for a total transaction of $1,101,642.50. Following the transaction, the executive vice president now owns 27,868 shares in the company, valued at approximately $1,706,915. The disclosure for this sale can be found here. 0.09% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the stock. Atlantic Securities lowered their target price on shares of Bristol-Myers Squibb from $90.00 to $85.00 and set an “overweight” rating on the stock in a report on Friday, July 28th. BMO Capital Markets decreased their price objective on shares of Bristol-Myers Squibb from $87.00 to $79.00 and set an “outperform” rating on the stock in a research note on Friday, July 28th. Wells Fargo & Company decreased their target price on shares of Bristol-Myers Squibb from $78.00 to $65.00 and set an “equal weight” rating on the stock in a research note on Friday, July 28th. Cantor Fitzgerald decreased their target price on shares of Bristol-Myers Squibb from $88.00 to $85.00 and set an “overweight” rating on the stock in a research note on Wednesday, July 19th. Finally, Bank of America decreased their target price on shares of Bristol-Myers Squibb from $85.00 to $80.00 and set a “buy” rating on the stock in a research note on Friday, July 28th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and seven have given a buy rating to the company. According to MarketBeat, Bristol-Myers Squibb currently has a consensus rating of “Hold” and a consensus price target of $71.14.

Bristol-Myers Squibb Trading Up 0.6 %

Shares of NYSE:BMY traded up $0.36 during mid-day trading on Thursday, reaching $60.01. 2,111,379 shares of the company’s stock were exchanged, compared to its average volume of 8,786,154. The firm has a market capitalization of $125.37 billion, a price-to-earnings ratio of 15.87, a PEG ratio of 1.58 and a beta of 0.42. The business’s fifty day moving average price is $61.88 and its 200-day moving average price is $65.33. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.28 and a current ratio of 1.39. Bristol-Myers Squibb has a twelve month low of $59.45 and a twelve month high of $81.43.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.99 by ($0.24). The firm had revenue of $11.23 billion during the quarter, compared to analyst estimates of $11.81 billion. Bristol-Myers Squibb had a net margin of 17.62% and a return on equity of 50.51%. Bristol-Myers Squibb’s quarterly revenue was down 5.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.93 EPS. On average, research analysts predict that Bristol-Myers Squibb will post 7.49 EPS for the current fiscal year.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.